Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Current Report · Items 2.02, 9.01 · 8-K

INOTIV INC

Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On February 9, 2026, Inotiv, Inc. issued a press release announcing financial results for the three months ended December 31, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

Filed Feb 9, 2026Accepted Feb 9, 2026, 7:30 AM ESTCIK 720154Accession 0001628280-26-006192
Share

Company context

Inotiv, Inc. is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The Company’s products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs and medical devices to market. Inotiv is committed to supporting discovery and development objectives as well as helping researchers realize the full potential of their critical research and development projects, all while working together to build a healthier and safer world. Further information about Inotiv can be found here: https://www.inotiv.com/.

Historical securities (2)

Recent company filings

  1. 15-12G filingJul 29, 2026
  2. 8-K15D5 filingJul 29, 2026
  3. EFFECT filingJul 27, 2026
  4. EFFECT filingJul 27, 2026
  5. EFFECT filingJul 27, 2026

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations
Item 2.02. Results of Operations and Financial Condition. On February 9, 2026, Inotiv, Inc. issued a press release announcing financial results for the three months ended December 31, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.
Filed exhibits (1)
EX-99.1 (by filename) notv-20260209xex991.htm

EX-99.1 2 notv-20260209xex991.htm EX-99.1 Document Exhibit 99.1 Inotiv Reports First Quarter Financial Results for Fiscal 2026 and Provides Business Update - First quarter fiscal 2026 revenue increased 0.8% compared to prior year quarter to $120.9 million - First quarter fiscal 2026 operating loss increased 5.3% compared to prior year quarter to $16.3 million - Conference call scheduled for today at 8:30 am ET WEST LAFAYETTE, IN, February 9, 2026 - Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months (“Q1 FY 2026”) ended December 31, 2025. Revenue by Segment (in millions of USD) 2025 2024 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── Three Mont…

Open exhibit ↗